Literature DB >> 33812489

Psoriasis.

Christopher E M Griffiths1, April W Armstrong2, Johann E Gudjonsson3, Jonathan N W N Barker4.   

Abstract

Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society. It is associated with several important medical conditions, including depression, psoriatic arthritis, and cardiometabolic syndrome. Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption. There are several phenotypes and research has separated pustular from chronic plaque forms. Immunological and genetic studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis. Immune targeting of these cytokines and of TNFα by biological therapies has revolutionised the care of severe chronic plaque disease. Psoriasis cannot currently be cured, but management should aim to minimise physical and psychological harm by treating patients early in the disease process, identifying and preventing associated multimorbidity, instilling lifestyle modifications, and employing a personalised approach to treatment.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33812489     DOI: 10.1016/S0140-6736(20)32549-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  105 in total

Review 1.  Skin Microbiota and the Cosmetic Industry.

Authors:  Maria João Carvalho; Ana L S Oliveira; Sílvia Santos Pedrosa; Manuela Pintado; Inês Pinto-Ribeiro; Ana Raquel Madureira
Journal:  Microb Ecol       Date:  2022-07-09       Impact factor: 4.552

2.  Novel Difluorocyclohexyl Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-02-01       Impact factor: 4.345

Review 3.  Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.

Authors:  Tung-Lin Lee; Tsen-Fang Tsai
Journal:  Inflamm Res       Date:  2022-01-04       Impact factor: 4.575

4.  Novel Difluorocyclohexyl Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-11-18       Impact factor: 4.345

5.  Delphinidin diminishes in vitro interferon-γ and interleukin-17 producing cells in patients with psoriatic disease.

Authors:  Sotirios G Tsiogkas; Αthanasios Mavropoulos; Dimitrios N Skyvalidas; Eleni Patrikiou; Niki Ntavari; Athina Ioanna Daponte; Maria G Grammatikopoulou; Efthimios Dardiotis; Aggeliki-Victoria Roussaki-Schulze; Lazaros I Sakkas; Efterpi Zafiriou; Dimitrios P Bogdanos
Journal:  Immunol Res       Date:  2021-11-25       Impact factor: 2.829

Review 6.  Genetic overlap between type 1 diabetes and other autoimmune diseases.

Authors:  Ana Márquez; Javier Martín
Journal:  Semin Immunopathol       Date:  2021-10-01       Impact factor: 9.623

7.  Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene.

Authors:  Niamh Kearney; Brian Kirby
Journal:  Am J Clin Dermatol       Date:  2022-08-23       Impact factor: 6.233

Review 8.  Roles of Infection in Psoriasis.

Authors:  Shihui Zhou; Zhirong Yao
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 9.  Roles of Lipids in the Permeability Barriers of Skin and Oral Mucosa.

Authors:  Philip W Wertz
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

10.  Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review.

Authors:  Tanja Todberg; Hannah Kaiser; Claus Zachariae; Alexander Egeberg; Anne-Sofie Halling; Lone Skov
Journal:  Acta Derm Venereol       Date:  2021-07-30       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.